{Reference Type}: Journal Article
{Title}: Preparation and evaluation of proliposomes formulation for enhancing the oral bioavailability of ginsenosides.
{Author}: Nguyen DT;Kim MH;Baek MJ;Kang NW;Kim DD;
{Journal}: J Ginseng Res
{Volume}: 48
{Issue}: 4
{Year}: 2024 Jul
{Factor}: 5.735
{DOI}: 10.1016/j.jgr.2024.03.004
{Abstract}: <B>UNASSIGNED: </B>This research main objective was to evaluate a proliposomes (PLs) formulation for the enhancement of oral bioavailability of ginsenosides, using ginsenoside Rg3 (Rg3) as a marker.<BR><B>UNASSIGNED: </B>A novel PLs formulation was prepared using a modified evaporation-on-matrix method. Soy phosphatidylcholine, Rg3-enriched extract, poloxamer 188 (Lutrol® F 68) and sorbitol were mixed and dissolved using a aqueous ethanolic solution, followed by the removal of ethanol and lyophilization. The characterization of Rg3-PLs formulations was performed by powder X-ray diffractometry (PXRD), transmission electron microscopy (TEM) and in vitro release. The enhancement of oral bioavailability was investigated and analyzed by non-compartmental parameters after oral administration of the formulations.<BR><B>UNASSIGNED: </B>PXRD of Rg3-PLs indicated that Rg3 was transformed from crystalline into its amorphous form during the preparation process. The Rg3-encapsulated liposomes with vesicular-shaped morphology were generated after the reconstitution by gentle hand-shaking in water; they had a mean diameter of approximately 350 nm, a negative zeta potential (-28.6 mV) and a high entrapment efficiency (97.3%). The results of the in vitro release study exhibited that significantly more amount of Rg3 was released from the PLs formulation in comparison with that from the suspension of Rg3-enriched extract (control group). The pharmacokinetic parameters after oral administration of PLs formulation in rats showed an approximately 11.8-fold increase in the bioavailability of Rg3, compared to that of the control group.<BR><B>UNASSIGNED: </B>The developed PLs formulation could be a favorable delivery system to improve the oral bioavailability of ginsenosides, including Rg3.